-
First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM.
Ultrasound Obstet Gynecol 2013;42:41-50. pdf -
First-trimester contingent screening for trisomies 21, 18 and 13 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Syngelaki A, Poon LC, Gil M, Wright D.
Fetal Diagn Ther 2014;35:185-92. pdf -
Maternal serum level of placental growth factor in diabetic pregnancies.
Ong CY, Lao TT, Spencer K, Nicolaides KH.
J Reprod Med 2004;49:477-80. -
Evaluation of human chorionic gonadotropin beta-subunit mRNA concentrations in maternal serum in aneuploid pregnancies: A feasibility study.
Ng EK, El-Sheikhah A, Chiu RW, Chan KC, Hogg M, Bindra R, Leung TN, Lau TK, Nicolaides KH, Lo YM.
Clin Chem 2004;50:1055-7. -
First trimester maternal serum placenta growth factor (PlGF)concentrations in pregnancies with fetal trisomy 21 or trisomy 18.
Spencer K, Liao AW, Ong CY, Geerts L, Nicolaides KH.
Prenat Diagn 2001;21:718-22. -
First-trimester maternal serum levels of placenta growth factor as predictor of preeclampsia and fetal growth restriction.
Ong CY, Liao AW, Cacho AM, Spencer K, Nicolaides KH.
Obstet Gynecol 2001;98:608-11.